The Orphan Advantage: How Rare Disease Assets Are Redefining Biopharma Deal Strategy

Over the past two decades, rare disease therapies have moved from an exception to a core engine of biopharma innovation. As internal R&D productivity declines and a historic patent cliff approaches, large pharmaceutical companies increasingly rely on external innovation to sustain growth. Rare disease assets have emerged as uniquely attractive sources of durable, lower‑volatility revenue; and are reshaping how companies build portfolios for the decade ahead.

In this white paper, part 3 of our Rare Disease Series, we explore:

1. Why Internal R&D Can’t Offset the Patent Cliff
2. The Orphan Advantage: A More Predictable Commercial Trajectory
3. How BD&L Behavior Has Shifted, and Why
4. What Drives Buy‑Side and Sell‑Side Decisions
5. What the Next Decade of Rare Disease BD&L Will Look Like

Rare disease assets are no longer niche opportunities; they are becoming strategic anchors in biopharma portfolios. As companies navigate volatility, orphan‑focused BD&L offers a disciplined, evidence‑backed approach to growth, differentiation, and long‑term revenue stability.